GlassScriptPhysician profile
Vahab Nemati
NPI 1710396791
$4,624.12
in general payments reported to CMS, 2019-2025
7 companies · $4,387 in 2025
The $4,387 reported for 2025 was more than what 84% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.84 · 2024: $206 · 2025: $4,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,657 · Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,656.89 |
| Food and Beverage | $935.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,148.15 | 2025 | Penumbra System |
| Angiodynamics, INC. | $1,562.12 | 2025 | Alphavac, Nanoknife |
| Inari Medical, INC. | $676.74 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $124.53 | 2025 | Obsidio |
| Stryker Corporation | $66.65 | 2024-2025 | Surpass Evolve, Spinejack |
| Progenics Pharmaceuticals, INC. | $31.84 | 2022 | |
| Terumo Medical Corporation | $14.09 | 2024 | Angio-Seal, Glidesheath Slender |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahab Nemati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.